Elena Carnero-Montoro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elena Carnero-Montoro has a total of 344 co-authors. Here are the top co-authors by number of shared publications:
- Jordana Tzenova Bell
Department of Twin Research and Genetic Epidemiology, King’s College London, London, United Kingdom
11 shared publications - Marta Eugenia Alarcón Riquelme
GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, PTS Granada , Granada
9 shared publications - Guillermo Barturen
Genyo. Pfizer–University of Granada–Junta de Andalucía Centre for Genomics and Oncological Research, Spain
6 shared publications - Elena Bosch
Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain
5 shared publications - Javier Martin
Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain
5 shared publications - Manuel Martínez-Bueno
Department of Plant Biochemistry and Molecular and Cellular Biology, Estacion Experimental del Zaidin, Consejo Superior de Investigaciones Cientificas, E-18008 Granada, Spain
5 shared publications
Latest Publications
- Open Access
- 3 September 2025
- Published by Springer Nature in Genes & Immunity
- Vol. 26 (5) , 1-12
Discovery of core genes for systemic lupus erythematosus via genome-wide aggregated trans-effects analysis
The “omnigenic” hypothesis postulates that the polygenic effects of common variants on a typical complex trait coalesce on relatively few core genes through trans-effects on their expression. Our aim was to identify core genes for systemic lupus erythematosus (SLE) by testing for association with genome-wide aggregated trans-effects (GATE) scores for gene expression in a large genetic dataset (5267/4909 SLE cases/controls). SLE was strongly associated with upregulation of expression of eight interferon-stimulated genes driven by shared trans-effects. We estimate that trans-effects on interferon signaling account for 9% of the total genetic effect on SLE risk. Outside this pathway, GATE analysis detected twenty putative core genes for SLE. Direct protein measurements for these genes were strongly associated with SLE in UK Biobank. Two putative core genes (TNFRSF17, TNFRSF13B) encode receptors (BCMA, TACI) expressed on B cells; their ligands (BAFF, APRIL) are targeted by drugs licensed or in development for SLE. Four genes (PDCD1, LAG3, TNFRSF9, CD27) encode receptors that have been characterized as immune checkpoints, and three (CD5L, SIGLEC1, CXCL13) are biomarkers of SLE disease activity. These results provide genetic support for existing drug targets in SLE (interferon signaling, BAFF/APRIL signaling) and identify other possible therapeutic targets including immune checkpoint receptors.
- 3 September 2025
- Published by Springer Nature in Genes & Immunity
- Vol. 26 (5) , 1-12
Open AccessDiscovery of core genes for systemic lupus erythematosus via genome-wide aggregated trans-effects analysis
The “omnigenic” hypothesis postulates that the polygenic effects of common variants on a typical complex trait coalesce on relatively few core genes through trans-effects on their expression. Our aim was to identify core genes for systemic lupus erythematosus (SLE) by testing for association with genome-wide aggregated trans-effects (GATE) scores for gene expression in a large genetic dataset (5267/4909 SLE cases/controls). SLE was strongly associated with upregulation of expression of eight interferon-stimulated genes driven by shared trans-effects. We estimate that trans-effects on interferon signaling account for 9% of the total genetic effect on SLE risk. Outside this pathway, GATE analysis detected twenty putative core genes for SLE. Direct protein measurements for these genes were strongly associated with SLE in UK Biobank. Two putative core genes (TNFRSF17, TNFRSF13B) encode receptors (BCMA, TACI) expressed on B cells; their ligands (BAFF, APRIL) are targeted by drugs licensed or in development for SLE. Four genes (PDCD1, LAG3, TNFRSF9, CD27) encode receptors that have been characterized as immune checkpoints, and three (CD5L, SIGLEC1, CXCL13) are biomarkers of SLE disease activity. These results provide genetic support for existing drug targets in SLE (interferon signaling, BAFF/APRIL signaling) and identify other possible therapeutic targets including immune checkpoint receptors.
- Open Access
- 16 July 2024
- Published by Springer Nature in npj Genomic Medicine
- Vol. 9 (1) , 1-13
Molecular subtypes explain lupus epigenomic heterogeneity unveiling new regulatory genetic risk variants
The heterogeneity of systemic lupus erythematosus (SLE) can be explained by epigenetic alterations that disrupt transcriptional programs mediating environmental and genetic risk. This study evaluated the epigenetic contribution to SLE heterogeneity considering molecular and serological subtypes, genetics and transcriptional status, followed by drug target discovery. We performed a stratified epigenome-wide association studies of whole blood DNA methylation from 213 SLE patients and 221 controls. Methylation quantitative trait loci analyses, cytokine and transcription factor activity - epigenetic associations and methylation-expression correlations were conducted. New drug targets were searched for based on differentially methylated genes. In a stratified approach, a total of 974 differential methylation CpG sites with dependency on molecular subtypes and autoantibody profiles were found. Mediation analyses suggested that SLE-associated SNPs in the HLA region exert their risk through DNA methylation changes. Novel genetic variants regulating DNAm in disease or in specific molecular contexts were identified. The epigenetic landscapes showed strong association with transcription factor activity and cytokine levels, conditioned by the molecular context. Epigenetic signals were enriched in known and novel drug targets for SLE. This study reveals possible genetic drivers and consequences of epigenetic variability on SLE heterogeneity and disentangles the DNAm mediation role on SLE genetic risk and novel disease-specific meQTLs. Finally, novel targets for drug development were discovered.
- 16 July 2024
- Published by Springer Nature in npj Genomic Medicine
- Vol. 9 (1) , 1-13
Open AccessMolecular subtypes explain lupus epigenomic heterogeneity unveiling new regulatory genetic risk variants
The heterogeneity of systemic lupus erythematosus (SLE) can be explained by epigenetic alterations that disrupt transcriptional programs mediating environmental and genetic risk. This study evaluated the epigenetic contribution to SLE heterogeneity considering molecular and serological subtypes, genetics and transcriptional status, followed by drug target discovery. We performed a stratified epigenome-wide association studies of whole blood DNA methylation from 213 SLE patients and 221 controls. Methylation quantitative trait loci analyses, cytokine and transcription factor activity - epigenetic associations and methylation-expression correlations were conducted. New drug targets were searched for based on differentially methylated genes. In a stratified approach, a total of 974 differential methylation CpG sites with dependency on molecular subtypes and autoantibody profiles were found. Mediation analyses suggested that SLE-associated SNPs in the HLA region exert their risk through DNA methylation changes. Novel genetic variants regulating DNAm in disease or in specific molecular contexts were identified. The epigenetic landscapes showed strong association with transcription factor activity and cytokine levels, conditioned by the molecular context. Epigenetic signals were enriched in known and novel drug targets for SLE. This study reveals possible genetic drivers and consequences of epigenetic variability on SLE heterogeneity and disentangles the DNAm mediation role on SLE genetic risk and novel disease-specific meQTLs. Finally, novel targets for drug development were discovered.
- Open Access
- 22 November 2023
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (1)
Response to the letter ‘testing the effectiveness of MyPROSLE in classifying patients with lupus nephritis’
Recently, a letter to the Editor entitled ‘Testing the Effectiveness of MyPROSLE in Classifying Patients with Lupus Nephritis’ has been submitted by Leventhal et al. to Briefings in Bioinformatics. In this letter, the authors test MyPROSLE, a web application we recently introduced [ 1], to characterizelupus patients from the molecular point of view. Leventhal et al. tested the application with independent datasets reporting that the software ‘did not perform sufficiently well to consider replacement of the standard kidney biopsy as a diagnostic procedure’. In this letter, we address in detail all the concerns described by Leventhal et al.
- 22 November 2023
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (1)
Open AccessResponse to the letter ‘testing the effectiveness of MyPROSLE in classifying patients with lupus nephritis’
Recently, a letter to the Editor entitled ‘Testing the Effectiveness of MyPROSLE in Classifying Patients with Lupus Nephritis’ has been submitted by Leventhal et al. to Briefings in Bioinformatics. In this letter, the authors test MyPROSLE, a web application we recently introduced [ 1], to characterizelupus patients from the molecular point of view. Leventhal et al. tested the application with independent datasets reporting that the software ‘did not perform sufficiently well to consider replacement of the standard kidney biopsy as a diagnostic procedure’. In this letter, we address in detail all the concerns described by Leventhal et al.
- Open Access
The Lupus Epigenome Relates to Genetics, Transcription and Serological Profiles with Dependency on Molecular Subtypes and Informs Drug Discovery
Objective The heterogeneity of systemic lupus erythematosus (SLE) can be explained by epigenetic alterations that disrupt transcriptional programs mediating environmental and genetic risk. This study evaluated the epigenetic contribution to SLE heterogeneity considering molecular and serological subtypes, genetics and transcriptional status, followed by drug target discovery. Methods We performed a stratified epigenome-wide association studies of whole blood DNA methylation from 213 SLE patients and 221 controls. Methylation quantitative trait loci analyses, cytokine and transcription factor activity - epigenetic associations and methylation-expression correlations were conducted. New drug targets were searched for based on differentially methylated genes. Results In a stratified approach, a total of 974 differential methylation CpG sites with dependency on molecular subtypes and autoantibody profiles were found. Mediation analyses suggested that SLE-associated SNPs in the HLA region exert their risk through DNA methylation changes. Novel genetic variants regulating DNAm in disease or in specific molecular contexts were identified. The epigenetic landscapes showed strong association with transcription factor activity and cytokine levels, conditioned by the molecular context. Epigenetic signals were enriched in known and novel potential drug targets for SLE. Conclusion This study expands the number of genes associated with SLE and reveals novel pathways of disease. The findings reveal possible genetic drivers and consequences of epigenetic variability on SLE heterogeneity and disentangles the DNAm mediation role on SLE genetic risk and the genetic architecture of DNAm in different molecular contexts. Finally, novel targets for drug development were discovered.
Open AccessThe Lupus Epigenome Relates to Genetics, Transcription and Serological Profiles with Dependency on Molecular Subtypes and Informs Drug Discovery
Objective The heterogeneity of systemic lupus erythematosus (SLE) can be explained by epigenetic alterations that disrupt transcriptional programs mediating environmental and genetic risk. This study evaluated the epigenetic contribution to SLE heterogeneity considering molecular and serological subtypes, genetics and transcriptional status, followed by drug target discovery. Methods We performed a stratified epigenome-wide association studies of whole blood DNA methylation from 213 SLE patients and 221 controls. Methylation quantitative trait loci analyses, cytokine and transcription factor activity - epigenetic associations and methylation-expression correlations were conducted. New drug targets were searched for based on differentially methylated genes. Results In a stratified approach, a total of 974 differential methylation CpG sites with dependency on molecular subtypes and autoantibody profiles were found. Mediation analyses suggested that SLE-associated SNPs in the HLA region exert their risk through DNA methylation changes. Novel genetic variants regulating DNAm in disease or in specific molecular contexts were identified. The epigenetic landscapes showed strong association with transcription factor activity and cytokine levels, conditioned by the molecular context. Epigenetic signals were enriched in known and novel potential drug targets for SLE. Conclusion This study expands the number of genes associated with SLE and reveals novel pathways of disease. The findings reveal possible genetic drivers and consequences of epigenetic variability on SLE heterogeneity and disentangles the DNAm mediation role on SLE genetic risk and the genetic architecture of DNAm in different molecular contexts. Finally, novel targets for drug development were discovered.
- Open Access
- 27 September 2022
- Published by BMJ
- Vol. 9 (Suppl 2) , A13.2-A14
S10.1 Genetic evaluation of molecular traits in systemic lupus erythematosus
Purpose Systemic Lupus Erythemathosus (SLE) is a prototypic systemic autoimmune disease characterized by a complex aetiology. Epigenetic alterations are known to be mediators of the environmental and genetic factors and to impact transcriptional programs. Here we aim to investigate genetic correlations between SLE and different molecular traits such as DNA methylation, gene expression and protein level by computing genotypic risk scores for the intermediate traits. Methods We use genotypes for 13,482 European ancestry individuals obtained from pre-existing projects studying SLE genetics, i) 4,174 SLE patients from a collection of SLE cohorts and 4,048 healthy controls from the University of Michigan Health and Retirement Study, ii) 696 SLE patients and 304 healthy controls from the International Consortium for Systemic Lupus Erythematosus Genetics and iii) 397 SLE patients and 561 healthy controls from the PRECISESADS Consortium. We computed genotypic risk scores for biomarkers using the GENOSCORES platform and tested the association between scores and the SLE phenotype using a logistic regression model for each score separately and adjusting for sex and 20 genetic principal components. Results We computed 1,716 locus-specific genotypic scores for loci affecting human plasma proteins (pQTLs). We detected 7 protein scores significantly associated with the SLE phenotype at Bonferroni correction. One of the 7 proteins, FCGR2B, is already known in SLE pathogenesis. Additionally, 4 protein scores were located within the HLA region in chromosome 6 (AMBN, ATF6, EDA, FIBCD1) and the remaining 2 (AXIN2, TREML4) scores were located in chromosome 14. Furthermore, we computed scores for the gene expression of these 7 proteins in different tissues and showed that scores for the gene expression of the AXIN2 gene were significantly associated with the SLE phenotype. Conclusions and Ongoing Analyses This study expands the list of candidate proteins associated with SLE and regions that might contain novel genes implicated in the SLE phenotype. Our findings demonstrate how genotypic scores for molecular traits can be used to identify and characterize genetic associations with complex disease traits. We aim to further explore the detected associations by considering DNA methylation traits and their association with SLE.
- 27 September 2022
- Published by BMJ
- Vol. 9 (Suppl 2) , A13.2-A14
Open AccessS10.1 Genetic evaluation of molecular traits in systemic lupus erythematosus
Purpose Systemic Lupus Erythemathosus (SLE) is a prototypic systemic autoimmune disease characterized by a complex aetiology. Epigenetic alterations are known to be mediators of the environmental and genetic factors and to impact transcriptional programs. Here we aim to investigate genetic correlations between SLE and different molecular traits such as DNA methylation, gene expression and protein level by computing genotypic risk scores for the intermediate traits. Methods We use genotypes for 13,482 European ancestry individuals obtained from pre-existing projects studying SLE genetics, i) 4,174 SLE patients from a collection of SLE cohorts and 4,048 healthy controls from the University of Michigan Health and Retirement Study, ii) 696 SLE patients and 304 healthy controls from the International Consortium for Systemic Lupus Erythematosus Genetics and iii) 397 SLE patients and 561 healthy controls from the PRECISESADS Consortium. We computed genotypic risk scores for biomarkers using the GENOSCORES platform and tested the association between scores and the SLE phenotype using a logistic regression model for each score separately and adjusting for sex and 20 genetic principal components. Results We computed 1,716 locus-specific genotypic scores for loci affecting human plasma proteins (pQTLs). We detected 7 protein scores significantly associated with the SLE phenotype at Bonferroni correction. One of the 7 proteins, FCGR2B, is already known in SLE pathogenesis. Additionally, 4 protein scores were located within the HLA region in chromosome 6 (AMBN, ATF6, EDA, FIBCD1) and the remaining 2 (AXIN2, TREML4) scores were located in chromosome 14. Furthermore, we computed scores for the gene expression of these 7 proteins in different tissues and showed that scores for the gene expression of the AXIN2 gene were significantly associated with the SLE phenotype. Conclusions and Ongoing Analyses This study expands the list of candidate proteins associated with SLE and regions that might contain novel genes implicated in the SLE phenotype. Our findings demonstrate how genotypic scores for molecular traits can be used to identify and characterize genetic associations with complex disease traits. We aim to further explore the detected associations by considering DNA methylation traits and their association with SLE.
- Open Access
- 10 August 2022
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 23 (5)
Scoring personalized molecular portraits identify Systemic Lupus Erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression
Objectives: Systemic Lupus Erythematosus is a complex autoimmune disease that leads to significant worsening of quality of life and mortality. Flares appear unpredictably during the disease course and therapies used are often only partially effective. These challenges are mainly due to the molecular heterogeneity of the disease, and in this context, personalized medicine-based approaches offer major promise. With this work we intended to advance in that direction by developing MyPROSLE, an omic-based analytical workflow for measuring the molecular portrait of individual patients to support clinicians in their therapeutic decisions. Methods: Immunological gene-modules were used to represent the transcriptome of the patients. A dysregulation score for each gene-module was calculated at the patient level based on averaged z-scores. Almost 6100 Lupus and 750 healthy samples were used to analyze the association among dysregulation scores, clinical manifestations, prognosis, flare and remission events and response to Tabalumab. Machine learning-based classification models were built to predict around 100 different clinical parameters based on personalized dysregulation scores. Results: MyPROSLE allows to molecularly summarize patients in 206 gene-modules, clustered into nine main lupus signatures. The combination of these modules revealed highly differentiated pathological mechanisms. We found that the dysregulation of certain gene-modules is strongly associated with specific clinical manifestations, the occurrence of relapses or the presence of long-term remission and drug response. Therefore, MyPROSLE may be used to accurately predict these clinical outcomes. Conclusions: MyPROSLE (https://myprosle.genyo.es) allows molecular characterization of individual Lupus patients and it extracts key molecular information to support more precise therapeutic decisions.
- 10 August 2022
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 23 (5)
Open AccessScoring personalized molecular portraits identify Systemic Lupus Erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression
Objectives: Systemic Lupus Erythematosus is a complex autoimmune disease that leads to significant worsening of quality of life and mortality. Flares appear unpredictably during the disease course and therapies used are often only partially effective. These challenges are mainly due to the molecular heterogeneity of the disease, and in this context, personalized medicine-based approaches offer major promise. With this work we intended to advance in that direction by developing MyPROSLE, an omic-based analytical workflow for measuring the molecular portrait of individual patients to support clinicians in their therapeutic decisions. Methods: Immunological gene-modules were used to represent the transcriptome of the patients. A dysregulation score for each gene-module was calculated at the patient level based on averaged z-scores. Almost 6100 Lupus and 750 healthy samples were used to analyze the association among dysregulation scores, clinical manifestations, prognosis, flare and remission events and response to Tabalumab. Machine learning-based classification models were built to predict around 100 different clinical parameters based on personalized dysregulation scores. Results: MyPROSLE allows to molecularly summarize patients in 206 gene-modules, clustered into nine main lupus signatures. The combination of these modules revealed highly differentiated pathological mechanisms. We found that the dysregulation of certain gene-modules is strongly associated with specific clinical manifestations, the occurrence of relapses or the presence of long-term remission and drug response. Therefore, MyPROSLE may be used to accurately predict these clinical outcomes. Conclusions: MyPROSLE (https://myprosle.genyo.es) allows molecular characterization of individual Lupus patients and it extracts key molecular information to support more precise therapeutic decisions.
- Open Access
- 2 December 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-18
Integrative epigenomics in Sjögren´s syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature
Primary Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by lymphocytic infiltration and damage of exocrine salivary and lacrimal glands. The etiology of SS is complex with environmental triggers and genetic factors involved. By conducting an integrated multi-omics study, we confirmed a vast coordinated hypomethylation and overexpression effects in IFN-related genes, what is known as the IFN signature. Stratified and conditional analyses suggest a strong interaction between SS-associatedHLAgenetic variation and the presence of Anti-Ro/SSA autoantibodies in driving the IFN epigenetic signature and determining SS. We report a novel epigenetic signature characterized by increased DNA methylation levels in a large number of genes enriched in pathways such as collagen metabolism and extracellular matrix organization. We identified potential new genetic variants associated with SS that might mediate their risk by altering DNA methylation or gene expression patterns, as well as disease-interacting genetic variants that exhibit regulatory function only in the SS population. Our study sheds new light on the interaction between genetics, autoantibody profiles, DNA methylation and gene expression in SS, and contributes to elucidate the genetic architecture of gene regulation in an autoimmune population.
- 2 December 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-18
Open AccessIntegrative epigenomics in Sjögren´s syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature
Primary Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by lymphocytic infiltration and damage of exocrine salivary and lacrimal glands. The etiology of SS is complex with environmental triggers and genetic factors involved. By conducting an integrated multi-omics study, we confirmed a vast coordinated hypomethylation and overexpression effects in IFN-related genes, what is known as the IFN signature. Stratified and conditional analyses suggest a strong interaction between SS-associatedHLAgenetic variation and the presence of Anti-Ro/SSA autoantibodies in driving the IFN epigenetic signature and determining SS. We report a novel epigenetic signature characterized by increased DNA methylation levels in a large number of genes enriched in pathways such as collagen metabolism and extracellular matrix organization. We identified potential new genetic variants associated with SS that might mediate their risk by altering DNA methylation or gene expression patterns, as well as disease-interacting genetic variants that exhibit regulatory function only in the SS population. Our study sheds new light on the interaction between genetics, autoantibody profiles, DNA methylation and gene expression in SS, and contributes to elucidate the genetic architecture of gene regulation in an autoimmune population.
- Open Access
- 6 July 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1
Publisher Correction: A multi-ethnic epigenome-wide association study of leukocyte DNA methylation and blood lipids
- 6 July 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1
Open AccessPublisher Correction: A multi-ethnic epigenome-wide association study of leukocyte DNA methylation and blood lipids
- Open Access
- 28 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
A multi-ethnic epigenome-wide association study of leukocyte DNA methylation and blood lipids
Here we examine the association between DNA methylation in circulating leukocytes and blood lipids in a multi-ethnic sample of 16,265 subjects. We identify 148, 35, and 4 novel associations among Europeans, African Americans, and Hispanics, respectively, and an additional 186 novel associations through a trans-ethnic meta-analysis. We observe a high concordance in the direction of effects across racial/ethnic groups, a high correlation of effect sizes between high-density lipoprotein and triglycerides, a modest overlap of associations with epigenome-wide association studies of other cardio-metabolic traits, and a largely non-overlap with lipid loci identified to date through genome-wide association studies. Thirty CpGs reached significance in at least 2 racial/ethnic groups including 7 that showed association with the expression of an annotated gene. CpGs annotated to CPT1A showed evidence of being influenced by triglycerides levels. DNA methylation levels of circulating leukocytes show robust and consistent association with blood lipid levels across multiple racial/ethnic groups.
- 28 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
Open AccessA multi-ethnic epigenome-wide association study of leukocyte DNA methylation and blood lipids
Here we examine the association between DNA methylation in circulating leukocytes and blood lipids in a multi-ethnic sample of 16,265 subjects. We identify 148, 35, and 4 novel associations among Europeans, African Americans, and Hispanics, respectively, and an additional 186 novel associations through a trans-ethnic meta-analysis. We observe a high concordance in the direction of effects across racial/ethnic groups, a high correlation of effect sizes between high-density lipoprotein and triglycerides, a modest overlap of associations with epigenome-wide association studies of other cardio-metabolic traits, and a largely non-overlap with lipid loci identified to date through genome-wide association studies. Thirty CpGs reached significance in at least 2 racial/ethnic groups including 7 that showed association with the expression of an annotated gene. CpGs annotated to CPT1A showed evidence of being influenced by triglycerides levels. DNA methylation levels of circulating leukocytes show robust and consistent association with blood lipid levels across multiple racial/ethnic groups.
- Open Access
An integrative multi-omics approach in Sjögren’s Syndrome identifies novel genetic drivers with regulatory function and disease-specificity
Primary Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by lymphocytic infiltration and damage of exocrine salivary and lacrimal glands. The etiology of SS is complex with environmental triggers and genetic factors involved. By conducting an integrated multi-omics study we identified vast coordinated hypomethylation and overexpression effects, that also exhibit increased variability, in many already known IFN-regulated genes. We report a novel epigenetic signature characterized by increased DNA methylation levels in a large number of novel genes enriched in pathways such as collagen metabolism and extracellular matrix organization. We identified new genetic variants associated with SS that mediate their risk by altering DNA methylation or gene expression patterns, as well as disease-interacting genetic variants that exhibit regulatory function only in the SS population. Our study sheds new light on the interaction between genetics, DNA methylation, gene expression and SS, and contributes to elucidate the genetic architecture of gene regulation in an autoimmune population.
Open AccessAn integrative multi-omics approach in Sjögren’s Syndrome identifies novel genetic drivers with regulatory function and disease-specificity
Primary Sjögren’s syndrome (SS) is a systemic autoimmune disease characterized by lymphocytic infiltration and damage of exocrine salivary and lacrimal glands. The etiology of SS is complex with environmental triggers and genetic factors involved. By conducting an integrated multi-omics study we identified vast coordinated hypomethylation and overexpression effects, that also exhibit increased variability, in many already known IFN-regulated genes. We report a novel epigenetic signature characterized by increased DNA methylation levels in a large number of novel genes enriched in pathways such as collagen metabolism and extracellular matrix organization. We identified new genetic variants associated with SS that mediate their risk by altering DNA methylation or gene expression patterns, as well as disease-interacting genetic variants that exhibit regulatory function only in the SS population. Our study sheds new light on the interaction between genetics, DNA methylation, gene expression and SS, and contributes to elucidate the genetic architecture of gene regulation in an autoimmune population.